First Trust Advisors LP Uni Qure N.V. Transaction History

First Trust Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $1.26 Million - $1.55 Million	67,152 Added 433.97%	82,626 $1.66 Million
Q4 2022 Feb 09, 2023	BUY	$18.12 - $27.32 $280,388 - $422,749	15,474 New	15,474 $350,000
Q3 2020 Nov 05, 2020	SELL	$35.98 - $47.66 $268,842 - $356,115	-7,472 Closed	0 $0
Q2 2020 Jul 22, 2020	SELL	$45.06 - $67.74 $178,437 - $268,250	-3,960 Reduced 34.64%	7,472 $337,000
Q1 2020 May 06, 2020	BUY	$40.01 - $73.97 $457,394 - $845,625	11,432 New	11,432 $542,000
Q4 2019 Feb 03, 2020	SELL	$37.13 - $74.62 $1.25 Million - $2.51 Million	-33,634 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$39.36 - $76.8 $522,700 - $1.02 Million	-13,280 Reduced 28.31%	33,634 $1.32 Million
Q2 2019 Jul 30, 2019	BUY	$52.76 - $82.19 $2.48 Million - $3.86 Million	46,914 New	46,914 $3.67 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.